Results for tag: "Castrate Resistant Prostate Cancer Drug"

The Castrate Resistant Prostate Cancer Drug market is a subset of the larger Prostate Cancer Drugs market. It is composed of drugs that are used to treat prostate cancer that has become resistant to hormone therapy, also known as androgen deprivation therapy. These drugs work by blocking the action of androgens, such as testosterone, which can fuel the growth of prostate cancer cells. Commonly used Castrate Resistant Prostate Cancer Drugs include abiraterone acetate, enzalutamide, and apalutamide. The Castrate Resistant Prostate Cancer Drug market is highly competitive, with many companies offering treatments. Some of the major players in the market include Johnson & Johnson, Astellas Pharma, Pfizer, Sanofi, and Bayer. Show Less Read more